Quest Diagnostics Inc vs Etsy Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Etsy Inc trades at $76.71 (market cap $6.90B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× Etsy Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Etsy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Etsy Inc for 67 Days on average.
| DGX | ETSY | |
|---|---|---|
Market Cap | $25.48B | $6.90B |
Volume | 941,866 | 2,923,867 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $87.03 |
52-Week Low | $173.49 | $44.05 |
Typical Hold Time | 56 Days | 67 Days |
Enterprise Value | $31.23B | $8.85B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
ETSY trades at $75.14, up 5.11% today, reflecting strong momentum. The stock shows a bullish technical outlook with consistent earnings beats and a 53.33% analyst buy rating. Recent news highlights AI integration to enhance personalization and renewed payment partnerships, supporting growth. Revenue reached $2.88B in 2025, though net income margin dipped to 5.65%. Cash flow improved with $593.18M net inflow in 2025, but high debt and negative equity pose financial risks.
The outlook is cautiously optimistic with a consensus price target of $85.94 offering ~14% upside. Strengths include robust gross margins and strategic AI initiatives, but risks involve elevated valuation multiples, competitive pressures, and sensitivity to consumer spending trends. Investors should weigh growth potential against balance sheet concerns.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →